Difference between revisions of "Seefeldt 2021 Sci Rep"
(Created page with "{{Publication |title=Seefeldt JM, Lassen TR, Vognstoft Hjortbak M, Riise Jespersen N, Kvist F, Hansen J, Boetker HE (2021) Cardioprotective effects of empagliflozin after isch...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Seefeldt JM, Lassen TR, Vognstoft Hjortbak M, | |title=Seefeldt JM, Lassen TR, Vognstoft Hjortbak M, Jespersen NR, Kvist F, Hansen J, Boetker HE (2021) Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci Rep 11:9544. | ||
|info=[https://pubmed.ncbi.nlm.nih.gov/33953281 PMID: 33953281 Open Access] | |info=[https://pubmed.ncbi.nlm.nih.gov/33953281 PMID: 33953281 Open Access] | ||
|authors=Seefeldt Jacob Marthinsen, Lassen Thomas Ravn, Vognstoft Hjortbak Marie, | |authors=Seefeldt Jacob Marthinsen, Lassen Thomas Ravn, Vognstoft Hjortbak Marie, Jespersen Nichlas Riise, Kvist Frederikke, Hansen Jakob, Boetker Hans Erik | ||
|year=2021 | |year=2021 | ||
|journal=Sci Rep | |journal=Sci Rep | ||
|abstract=The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces mortality and hospitalisation for heart failure following myocardial infarction irrespective of diabetes status. While the findings suggest an inherent cardioprotective capacity, the mechanism remains unknown. We studied infarct size (IS) ''ex vivo'' in isolated hearts exposed to global IR injury and ''in vivo'' in rats subjected to regional myocardial ischemia reperfusion (IR) injury, in whom we followed left ventricular dysfunction for 28 days. We compared rats that were given EMPA orally for 7 days before, EMPA 1.5 h before IR injury and at onset of reperfusion and continued orally during the follow-up period. We used echocardiography, high resolution respirometry, microdialysis and plasma levels of β-hydroxybutyrate to assess myocardial performance, mitochondrial respiration and intermediary metabolism, respectively. Pretreatment with EMPA for 7 days reduced IS ''in vivo'' (65 ± 7% vs. 46 ± 8%, p < 0.0001 while administration 1.5 h before IR, at onset of reperfusion or ''ex vivo'' did not. EMPA alleviated LV dysfunction irrespective of the reduction in IS. EMPA improved mitochondrial respiration and modulated myocardial interstitial metabolism while the concentration of β-hydroxybutyric acid was only transiently increased without any association with IS reduction. EMPA reduces infarct size and yields cardioprotection in non-diabetic rats with ischemic LV dysfunction by an indirect, delayed intrinsic mechanism that also improves systolic function beyond infarct size reduction. The mechanism involves enhanced mitochondrial respiratory capacity and modulated myocardial metabolism but not hyperketonemia. | |abstract=The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces mortality and hospitalisation for heart failure following myocardial infarction irrespective of diabetes status. While the findings suggest an inherent cardioprotective capacity, the mechanism remains unknown. We studied infarct size (IS) ''ex vivo'' in isolated hearts exposed to global IR injury and ''in vivo'' in rats subjected to regional myocardial ischemia reperfusion (IR) injury, in whom we followed left ventricular dysfunction for 28 days. We compared rats that were given EMPA orally for 7 days before, EMPA 1.5 h before IR injury and at onset of reperfusion and continued orally during the follow-up period. We used echocardiography, high resolution respirometry, microdialysis and plasma levels of β-hydroxybutyrate to assess myocardial performance, mitochondrial respiration and intermediary metabolism, respectively. Pretreatment with EMPA for 7 days reduced IS ''in vivo'' (65 ± 7% vs. 46 ± 8%, p < 0.0001 while administration 1.5 h before IR, at onset of reperfusion or ''ex vivo'' did not. EMPA alleviated LV dysfunction irrespective of the reduction in IS. EMPA improved mitochondrial respiration and modulated myocardial interstitial metabolism while the concentration of β-hydroxybutyric acid was only transiently increased without any association with IS reduction. EMPA reduces infarct size and yields cardioprotection in non-diabetic rats with ischemic LV dysfunction by an indirect, delayed intrinsic mechanism that also improves systolic function beyond infarct size reduction. The mechanism involves enhanced mitochondrial respiratory capacity and modulated myocardial metabolism but not hyperketonemia. | ||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
|mipnetlab=DK Aarhus Boetker HE | |||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |area=Respiration, Pharmacology;toxicology | ||
|diseases=Cardiovascular | |||
|injuries=Ischemia-reperfusion | |injuries=Ischemia-reperfusion | ||
|organism=Rat | |organism=Rat | ||
Latest revision as of 09:36, 15 July 2021
| Seefeldt JM, Lassen TR, Vognstoft Hjortbak M, Jespersen NR, Kvist F, Hansen J, Boetker HE (2021) Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci Rep 11:9544. |
Seefeldt Jacob Marthinsen, Lassen Thomas Ravn, Vognstoft Hjortbak Marie, Jespersen Nichlas Riise, Kvist Frederikke, Hansen Jakob, Boetker Hans Erik (2021) Sci Rep
Abstract: The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces mortality and hospitalisation for heart failure following myocardial infarction irrespective of diabetes status. While the findings suggest an inherent cardioprotective capacity, the mechanism remains unknown. We studied infarct size (IS) ex vivo in isolated hearts exposed to global IR injury and in vivo in rats subjected to regional myocardial ischemia reperfusion (IR) injury, in whom we followed left ventricular dysfunction for 28 days. We compared rats that were given EMPA orally for 7 days before, EMPA 1.5 h before IR injury and at onset of reperfusion and continued orally during the follow-up period. We used echocardiography, high resolution respirometry, microdialysis and plasma levels of β-hydroxybutyrate to assess myocardial performance, mitochondrial respiration and intermediary metabolism, respectively. Pretreatment with EMPA for 7 days reduced IS in vivo (65 ± 7% vs. 46 ± 8%, p < 0.0001 while administration 1.5 h before IR, at onset of reperfusion or ex vivo did not. EMPA alleviated LV dysfunction irrespective of the reduction in IS. EMPA improved mitochondrial respiration and modulated myocardial interstitial metabolism while the concentration of β-hydroxybutyric acid was only transiently increased without any association with IS reduction. EMPA reduces infarct size and yields cardioprotection in non-diabetic rats with ischemic LV dysfunction by an indirect, delayed intrinsic mechanism that also improves systolic function beyond infarct size reduction. The mechanism involves enhanced mitochondrial respiratory capacity and modulated myocardial metabolism but not hyperketonemia.
• Bioblast editor: Plangger M • O2k-Network Lab: DK Aarhus Boetker HE
Labels: MiParea: Respiration, Pharmacology;toxicology
Pathology: Cardiovascular
Stress:Ischemia-reperfusion
Organism: Rat
Tissue;cell: Heart
Preparation: Permeabilized tissue
Coupling state: LEAK, OXPHOS
Pathway: N, S, NS, ROX
HRR: Oxygraph-2k
2021-07
